, . , . , , , .
:
1) ();
2) ();
3) ()
, . .
:
1) , , , (1);
2) , , (1);
3) , ( ) (1);
4) , , (2);
5) , , ( ), (2);
6) , ; , [2);
7) ().
.
: , 1,36%, -2,27%, 3,86%. : 4-5 2,0-2,5-3.
:
7.1.1., . (1)).
7.1.2 ( ), , . 1-2 , (2).
7.1.3 , , , (1).
7.1.4 : 2-3 , 1 1 ().
|
|
|
1. .. . . 2010; .153
2. Biesen W., Vanholder R, Veys N. et al. An Evaluation of an Integrative Care Approach for End-Stage Renal Disease Patients J Am Soc Nephrol. 2000; 11:116-125.
3. Barone RJ, Cámpora MI, Gimenez NS, Ramirez L, Panese SA, Santopietro M. Peritoneal Dialysis as a First versus Second Option after Previous Haemodialysis: A Very Long-Term Assessment. Int J Nephrol. 2014;2014:693-670.
4. Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. Adv Chronic Kidney Dis. 2011;18(6): 428-32.
5. Heaf JG, Wehberg S. Relative survival of peritoneal dialysis and haemodialysis patients: effect of cohort and mode of dialysis initiation. PLoS One. 2014; 10; 9(3): 90-119.
6. Smyth A, McCann E, Redahan L, Lambert B, Mellotte GJ, Wall CA. Peritoneal dialysis in an ageing population: a 10-year experience. Int Urol Nephrol. 2012;44(1):283-93.
7. Roszkowska-Blaim M, Skrzypczyk P, Jander A et al. The effect of peritoneal dialysis method on residual renal function in children. Adv Perit Dial. 2012; 28:112-9.
8. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556564.
9. Roszkowska-Blaim M, Skrzypczyk P. Residual renal function in children treated with chronic peritoneal dialysis. ScientificWorldJournal. 2013 Nov 24; 2013: 154-153.
10. McCarthy J. The use of polysulphone dialyzers slows the rate of intrinsic renal function loss in chronic hemodialysis patients [Abstract]. J Am Soc Nephrol 1993; 4: 367.
11. Niwa T, Ise M. Indoxyl sulphate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96104.
12. Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB Role for uremic toxin in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 4619.
13. Lobbedez T, Lecouf A, Abbadie O, Ficheux M, Hurault de Ligny B, Ryckelynck JP.
Peritoneal dialysis and renal transplantation. Contrib Nephrol. 2009; 163: 250-256.
14. Pereira B, Levey A. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 98199.
15. Cendoroglo M, Draibe S, Silva A, Ferraz M, Granato C, Pereira C, et al. Incidence and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: Evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 2406.
16. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, Benamar L. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl. 2014; 25(3): 672-9.
17. Hanko J, Romann A, Taylor P, Copland M, Beaulieu M. Optimizing AVF creation prior to dialysis start: the role of predialysis renal replacement therapy choices. Nephrol Dial Transplant. 2012; 27(11): 4205-10.
18. Peter G. Blake1, Joanne M. Bargman2, K. Scott Brimble et al. CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONS ON PERITONEAL DIALYSIS ADEQUACY Perit Dial Int 2011;31(2): 218-239.
